2023
Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation
Leapman M, Wang R, Loeb S, Seibert T, Gaylis F, Lowentritt B, Brown G, Chen R, Lin D, Witte J, Cooperberg M, Catalona W, Gross C, Ma X. Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation. Journal Of Urology 2023, 209: 710-718. PMID: 36753746, DOI: 10.1097/ju.0000000000003159.Peer-Reviewed Original ResearchMeSH KeywordsAgedHumansMaleMedicareProstateProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesUnited StatesConceptsIntermediate-risk prostate cancerMixed-effects Poisson regressionPSA testingProstate biopsyProstate cancerEffects Poisson regressionMedicare beneficiariesPoisson regressionAdditional prostate biopsyRetrospective cohort studyProstate MRILocalized prostate cancerRepeat prostate biopsyRate of biopsyRace/ethnicityCensus tract povertyMedian followCohort studyMedian ageMonitoring testsProvider factorsPSA testClinical riskBiopsySociodemographic factors
2022
Mediators of Racial Disparity in the Use of Prostate Magnetic Resonance Imaging Among Patients With Prostate Cancer
Leapman MS, Dinan M, Pasha S, Long J, Washington SL, Ma X, Gross CP. Mediators of Racial Disparity in the Use of Prostate Magnetic Resonance Imaging Among Patients With Prostate Cancer. JAMA Oncology 2022, 8: 687-696. PMID: 35238879, PMCID: PMC8895315, DOI: 10.1001/jamaoncol.2021.8116.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBlack or African AmericanCohort StudiesHumansMagnetic Resonance ImagingMaleMedicareProstateProstatic NeoplasmsUnited StatesConceptsProstate magnetic resonance imagingMagnetic resonance imagingPopulation-based cohort studyProstate cancerWhite patientsRacial disparitiesCohort studyMRI useIndividual-level socioeconomic statusEligible male patientsSocioeconomic statusNeighborhood-level socioeconomic statusLocalized prostate cancerProstate cancer diagnosisObserved racial disparitiesProstate magnetic resonanceMediation analysisPathologic factorsMale patientsUS SurveillanceBlack patientsMedicare databaseMAIN OUTCOMEUS adultsNew diagnosisChanges in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening
Leapman MS, Wang R, Park H, Yu JB, Sprenkle PC, Cooperberg MR, Gross CP, Ma X. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. JAMA Oncology 2022, 8: 41-47. PMID: 34762100, PMCID: PMC8587214, DOI: 10.1001/jamaoncol.2021.5143.Peer-Reviewed Original ResearchConceptsProstate cancer screeningUS Preventive Services Task ForcePSA testingCancer screeningInterrupted time series analysisCohort studyUS Preventive Services Task Force (USPSTF) recommendationDraft statementLarge national cohort studyEligible beneficiariesPSA testing ratesRetrospective cohort studyRate of PSANational cohort studyProstate-specific antigenAge-adjusted ratesTask Force recommendationsUSPSTF guidelinesMedian ageGuideline changesProstate cancerMedian numberMAIN OUTCOMEClaims dataTesting rates
2021
Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management
Leapman MS, Wang R, Park HS, Yu JB, Sprenkle PC, Dinan MA, Ma X, Gross CP. Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management. JAMA Network Open 2021, 4: e2128646. PMID: 34623406, PMCID: PMC8501394, DOI: 10.1001/jamanetworkopen.2021.28646.Peer-Reviewed Original ResearchConceptsProstate magnetic resonance imagingMagnetic resonance imagingHospital referral regionsProportion of patientsProstate cancerGenomic testingCohort studyReferral regionsRetrospective cohort studyProstate cancer carePatient-level analysisCommercial insurance claimsProstate cancer managementUS hospital referral regionsYears of ageProportion of menPatients 40Definitive treatmentCancer careTesting uptakeHRR levelMAIN OUTCOMECancer managementPatientsRegional uptakeRegional Adoption of Commercial Gene Expression Testing for Prostate Cancer
Leapman MS, Wang R, Ma S, Gross CP, Ma X. Regional Adoption of Commercial Gene Expression Testing for Prostate Cancer. JAMA Oncology 2021, 7: 52-58. PMID: 33237277, PMCID: PMC7689565, DOI: 10.1001/jamaoncol.2020.6086.Peer-Reviewed Original ResearchConceptsProstate cancerCohort studyGenomic testingTissue-based genomic testsProportion of patientsDynamic cohort studyProstate cancer careProstate cancer screeningHospital referral region levelCommercial health insuranceGene expression testingEligible patientsMedian ageCancer careCancer screeningInclusion criteriaFindings highlight factorsHRR levelMAIN OUTCOMEAdministrative claimsGroup 2Group 1Medicare beneficiariesPatientsMedian household income
2020
National trends in the management of patients with positive surgical margins at radical prostatectomy
Ghabili K, Park HS, Yu JB, Sprenkle PC, Kim SP, Nguyen KA, Ma X, Gross CP, Leapman MS. National trends in the management of patients with positive surgical margins at radical prostatectomy. World Journal Of Urology 2020, 39: 1141-1151. PMID: 32562045, DOI: 10.1007/s00345-020-03298-6.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyPositive surgical marginsUse of ADTPost-prostatectomy radiation therapyRadiation therapySurgical marginsRadical prostatectomyInitial courseNode-negative prostate cancerPost-operative radiation therapyMultivariable logistic regression modelNational Cancer DatabaseAdverse pathologic featuresManagement of patientsPost-operative managementLogistic regression modelsDeprivation therapySurgical cancersPrimary endpointRT useSecondary endpointsPathologic characteristicsPathologic featuresUninsured statusCancer Database
2018
Prostate cancer risk factors in black and white men in the NIH-AARP Diet and Health Study
Layne TM, Graubard BI, Ma X, Mayne ST, Albanes D. Prostate cancer risk factors in black and white men in the NIH-AARP Diet and Health Study. Prostate Cancer And Prostatic Diseases 2018, 22: 91-100. PMID: 30108373, PMCID: PMC6676904, DOI: 10.1038/s41391-018-0070-9.Peer-Reviewed Original ResearchConceptsProstate cancer riskHazard ratioWhite menAdvanced diseaseBlack raceRisk factorsCancer riskHealth StudyRisk associationDietary vitamin D intakeProstate cancer risk factorsProportional hazards regression modelsBlack menNon-Hispanic white menPositive risk associationVitamin D intakeHistory of diabetesNIH-AARP DietCancer risk factorsProstate cancer screeningHazards regression modelsConfidence intervalsHealth-related factorsCancer risk associationsRace-specific associationsAssociation Between Prostate Magnetic Resonance Imaging and Observation for Low-risk Prostate Cancer
Leapman MS, Wang R, Park HS, Yu JB, Weinreb JC, Gross CP, Ma X. Association Between Prostate Magnetic Resonance Imaging and Observation for Low-risk Prostate Cancer. Urology 2018, 124: 98-106. PMID: 30107188, DOI: 10.1016/j.urology.2018.07.041.Peer-Reviewed Original ResearchMeSH KeywordsAgedHumansMagnetic Resonance ImagingMaleProstatic NeoplasmsRisk AssessmentWatchful WaitingConceptsLow-risk prostate cancerProstate magnetic resonance imagingMagnetic resonance imagingProstate cancerDefinitive treatmentPCa diagnosisEnd Results-Medicare databaseResonance imagingMultivariable logistic regression analysisPropensity scoreDiagnosis of PCaUse of MRIConditional logistic regression modelsLogistic regression analysisLogistic regression modelsInitial managementMultivariable analysisGreater oddsPatientsSocioeconomic statusDiagnosisHigher likelihoodRegression analysisDemographic factorsCancer
2017
Serum 25‐hydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men
Layne TM, Weinstein SJ, Graubard BI, Ma X, Mayne ST, Albanes D. Serum 25‐hydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men. Cancer 2017, 123: 2698-2704. PMID: 28369777, PMCID: PMC5498231, DOI: 10.1002/cncr.30634.Peer-Reviewed Original ResearchConceptsProstate cancer riskD binding proteinVitamin D statusCancer riskD statusOdds ratioProstate cancerLow vitamin D statusSerum DBPOvarian Cancer Screening TrialDecreased prostate cancer riskOverall prostate cancerCancer Screening TrialBlack menProstate cancer screeningApparent inverse associationConfidence intervalsVitamin D binding proteinConditional logistic regressionProstate cancer casesNonaggressive diseaseCohort entryCancer screeningBlood drawInverse association
2016
Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population‐Based Study
Wang R, Zeidan AM, Yu JB, Soulos PR, Davidoff AJ, Gore SD, Huntington SF, Gross CP, Ma X. Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population‐Based Study. The Prostate 2016, 77: 437-445. PMID: 27868212, PMCID: PMC5785924, DOI: 10.1002/pros.23281.Peer-Reviewed Original ResearchConceptsMDS/acute myeloid leukemiaAcute myeloid leukemiaProstate cancer patientsElderly prostate cancer patientsImpact of radiotherapyCancer patientsMyelodysplastic syndromeNational Cancer Institute's SurveillanceSubsequent myelodysplastic syndromeEnd Results-MedicareRetrospective cohort studyRole of radiotherapyInformed treatment decisionsUnderwent radiotherapyIMRT groupCohort studyPatient characteristicsMedian timeMyeloid leukemiaProstate cancerTreatment decisionsPatientsRadiotherapyMyeloid malignanciesSurgery
2014
Understanding Regional Variation in Medicare Expenditures for Initial Episodes of Prostate Cancer Care
Wang SY, Wang R, Yu JB, Ma X, Xu X, Kim SP, Soulos PR, Saraf A, Gross CP. Understanding Regional Variation in Medicare Expenditures for Initial Episodes of Prostate Cancer Care. Medical Care 2014, 52: 680-687. PMID: 25023913, PMCID: PMC4129645, DOI: 10.1097/mlr.0000000000000158.Peer-Reviewed Original ResearchConceptsAncillary proceduresPatient characteristicsTreatment modalitiesTreatment intensityEnd Results-Medicare databaseProstate cancer careSpecific treatment modalitiesContribution of patientHospital referral regionsInitial treatmentCancer careInitial episodeNoncancer controlsProstate cancerQuintile 5Referral regionsSubstantial geographic variationCare costsMedicare expendituresCostly modalityTreatment factorsMean expenditureLowest expenditure quintileSurgeryModalities
2013
The cost implications of prostate cancer screening in the Medicare population
Ma X, Wang R, Long JB, Ross JS, Soulos PR, Yu JB, Makarov DV, Gold HT, Gross CP. The cost implications of prostate cancer screening in the Medicare population. Cancer 2013, 120: 96-102. PMID: 24122801, PMCID: PMC3867600, DOI: 10.1002/cncr.28373.Peer-Reviewed Original ResearchConceptsProstate cancerScreening costsAnnual screening costsPopulation-based cohortProstate cancer screeningHospital referral region levelMale Medicare beneficiariesProstate-specific antigenCancer screeningLowest quartileHRR levelMedicare populationMedicare beneficiariesOlder menNational feeCancerService Medicare programCancer diagnosisMenQuartilePSACost implicationsAnnual expenditureMedicare programBiopsy
2012
Impact of the 2008 US Preventive Services Task Force Recommendation to Discontinue Prostate Cancer Screening Among Male Medicare Beneficiaries
Ross JS, Wang R, Long JB, Gross CP, Ma X. Impact of the 2008 US Preventive Services Task Force Recommendation to Discontinue Prostate Cancer Screening Among Male Medicare Beneficiaries. JAMA Internal Medicine 2012, 172: 1601-1603. PMID: 22987029, PMCID: PMC3597450, DOI: 10.1001/archinternmed.2012.3726.Peer-Reviewed Original Research
2011
Genetic variation in nucleotide excision repair pathway genes, pesticide exposure and prostate cancer risk
Barry KH, Koutros S, Andreotti G, Sandler DP, Burdette LA, Yeager M, Freeman L, Lubin JH, Ma X, Zheng T, Alavanja MC, Berndt SI. Genetic variation in nucleotide excision repair pathway genes, pesticide exposure and prostate cancer risk. Carcinogenesis 2011, 33: 331-337. PMID: 22102698, PMCID: PMC3271261, DOI: 10.1093/carcin/bgr258.Peer-Reviewed Original ResearchConceptsProstate cancer riskCancer riskSingle nucleotide polymorphismsPesticide exposurePesticide applicatorsPesticide manufacturing workersCase-control studyInteraction p valueProstate cancer casesNucleotide excision repair pathway genesWild-type TT genotypeLogistic regression modelsHuman biomonitoring studiesCancer casesLifetime daysTT genotypeERCC1 rs2298881Male controlsFalse discovery rate methodIntensity scoresSignificant associationNucleotide excision repair pathwayGenotype groupsManufacturing workersUnderlying mechanismGenetic Variation in Base Excision Repair Pathway Genes, Pesticide Exposure, and Prostate Cancer Risk
Barry KH, Koutros S, Berndt SI, Andreotti G, Hoppin JA, Sandler DP, Burdette LA, Yeager M, Freeman LE, Lubin JH, Ma X, Zheng T, Alavanja MC. Genetic Variation in Base Excision Repair Pathway Genes, Pesticide Exposure, and Prostate Cancer Risk. Environmental Health Perspectives 2011, 119: 1726-1732. PMID: 21810555, PMCID: PMC3261977, DOI: 10.1289/ehp.1103454.Peer-Reviewed Original ResearchConceptsProstate cancer riskCancer riskSingle nucleotide polymorphismsPesticide applicatorsCT/TT genotypesPesticide manufacturing workersCase-control studyProstate cancer casesLogistic regression modelsTag single nucleotide polymorphismsBase excision repair pathway genesProstate cancerCancer casesFamily historyOxidative DNA damageTT genotypeCC genotypeMale controlsExposure variablesPesticide exposureBase excision repairManufacturing workersUnderlying mechanismRiskBER genes
2009
Intake of meat, meat mutagens, and iron and the risk of breast cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
Ferrucci LM, Cross AJ, Graubard BI, Brinton LA, McCarty CA, Ziegler RG, Ma X, Mayne ST, Sinha R. Intake of meat, meat mutagens, and iron and the risk of breast cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. British Journal Of Cancer 2009, 101: 178-184. PMID: 19513076, PMCID: PMC2713710, DOI: 10.1038/sj.bjc.6605118.Peer-Reviewed Original ResearchConceptsOvarian Cancer Screening TrialCancer Screening TrialBreast cancerDietary ironMeat mutagensHazard ratioScreening TrialSubsequent breast cancer riskCox proportional hazards regressionInvasive breast cancer casesRed meatFood frequency questionnaireInvasive breast cancerQuintiles of intakeProportional hazards regressionHaem iron intakeIntake of meatBreast cancer riskConfidence intervalsBreast cancer casesHeterocyclic aminesFrequency questionnaireHazards regressionProspective studyIron intakeXenobiotic Metabolizing Gene Variants, Dietary Heterocyclic Amine Intake, and Risk of Prostate Cancer
Koutros S, Berndt SI, Sinha R, Ma X, Chatterjee N, Alavanja MC, Zheng T, Huang WY, Hayes RB, Cross AJ. Xenobiotic Metabolizing Gene Variants, Dietary Heterocyclic Amine Intake, and Risk of Prostate Cancer. Cancer Research 2009, 69: 1877-1884. PMID: 19223546, PMCID: PMC2662592, DOI: 10.1158/0008-5472.can-08-2447.Peer-Reviewed Original ResearchConceptsProstate cancer riskProstate cancerOdds ratioCancer riskSingle nucleotide polymorphismsDietary Heterocyclic Amine IntakeOvarian Cancer Screening TrialHeterocyclic amine intakeCancer Screening TrialUnconditional logistic regressionCase-control studyDietary heterocyclic aminesProstate cancer casesHeterocyclic aminesHCA intakeCancer casesLow intakeScreening TrialHCA metabolismMalignant transformationLogistic regressionCancerIntakeGene variantsConfidence intervals
2008
Meat and Meat Mutagens and Risk of Prostate Cancer in the Agricultural Health Study
Koutros S, Cross AJ, Sandler DP, Hoppin JA, Ma X, Zheng T, Alavanja MC, Sinha R. Meat and Meat Mutagens and Risk of Prostate Cancer in the Agricultural Health Study. Cancer Epidemiology Biomarkers & Prevention 2008, 17: 80-87. PMID: 18199713, PMCID: PMC2935655, DOI: 10.1158/1055-9965.epi-07-0392.Peer-Reviewed Original ResearchConceptsAgricultural Health StudyProstate cancerHealth StudyMeat mutagensIncident prostate cancer casesCox proportional hazards regressionComplete dietary dataUnderlying time metricIncident prostate cancerProportional hazards regressionMeat cooking methodsProstate cancer riskProstate cancer casesCarcinogenic heterocyclic aminesAdvanced diseaseHighest tertileSmoking statusHazards regressionBorderline significanceHighest quintileIncident diseaseRelative riskCancer casesFamily historyState of residence